AN2 Therapeutics, Inc. Class of Warrant or Right, Outstanding
AN2 Therapeutics, Inc. (ANTX) had Class of Warrant or Right, Outstanding of 2.95 million shares as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2026-03-17
- 2025-12-31: Class of Warrant or Right, Outstanding 2.95M shares.
- 2025-09-30: Class of Warrant or Right, Outstanding 2.95M shares.
- 2025-06-30: Class of Warrant or Right, Outstanding 2.95M shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2025-12-31 | 2.95M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 2.95M shares 10-Q · filed 2025-11-12 |
| 2025-06-30 | 2.95M shares 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |